A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/30/2011	EP2390248A1 Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
11/30/2011	EP2389999A2 Method for mixing by producing shear and/or cavitation in order to produce a stable composition
11/30/2011	EP2389940A2 Vaginal applicator with two openings
11/30/2011	EP2389939A1 Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
11/30/2011	EP2389938A1 Antifungal medicinal compositions
11/30/2011	EP2389937A1 Medicinal composition for improving brain function
11/30/2011	EP2389936A1 Aminaphtone for use in the treatment and/or prevention of migraine
11/30/2011	EP2389935A1 Controlled-Release oral Solution Formulations of Pregabalin
11/30/2011	EP2389934A1 Controlled-Release Tablet Formulations of Pregabalin
11/30/2011	EP2389933A1 Controlled-Release Pregabalin Compositions
11/30/2011	EP2389932A1 Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
11/30/2011	EP2389931A1 Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
11/30/2011	EP2389930A1 Novel composition for tumor growth control
11/30/2011	EP2389929A1 Pharmaceutical formulations of tenofovir
11/30/2011	EP2389928A2 Biodegradable polymer encapsulated microsphere particulate film and method of making thereof
11/30/2011	EP2389927A1 Pharmaceutical formulations of rasagiline
11/30/2011	EP2389926A2 Hydrogel implants with varying degrees of crosslinking
11/30/2011	EP2389925A2 Hydrogel implant with varying degrees of crosslinking
11/30/2011	EP2389923A1 Stable ready to use injectable paracetamol formulation
11/30/2011	EP2389896A2 Hydrogel implants with varying degrees of crosslinking
11/30/2011	EP2389895A2 Hydrogel implants with varying degrees of crosslinking
11/30/2011	EP2389894A2 Hydrogel implants with varying degrees of crosslinking
11/30/2011	EP2389382A1 Amino-heterocyclic compounds used as pde9 inhibitors
11/30/2011	EP2389381A1 Spiroindolinone derivative prodrugs
11/30/2011	EP2389380A1 N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use
11/30/2011	EP2389379A1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
11/30/2011	EP2389378A1 Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
11/30/2011	EP2389377A1 Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
11/30/2011	EP2389376A1 Novel bicyclic antibiotics
11/30/2011	EP2389375A2 Hydroxamic acid derivatives
11/30/2011	EP2389374A1 Substituted pyrazinone amides
11/30/2011	EP2389373A1 Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
11/30/2011	EP2389372A1 Compositions and methods for inhibition of the jak pathway
11/30/2011	EP2389371A2 Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use
11/30/2011	EP2389369A1 Pentafluorosulpholane-containing antidiabetic compounds
11/30/2011	EP2389368A1 Bridged and fused antidiabetic compounds
11/30/2011	EP2389366A1 Benzodiazepin-2-on derivatives
11/30/2011	EP2389365A1 Process for the preparation of rosuvastatin salts
11/30/2011	EP2389364A2 New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine
11/30/2011	EP2389363A1 Salts and polymorphs of a kinesin inhibitor compound
11/30/2011	EP2389362A1 Phenylcyclopropylamine derivatives and their medical use
11/30/2011	EP2389355A1 New crystals of a benzoylbenzeneacetamide derivative
11/30/2011	EP2389352A2 Arginase inhibitors and methods of use
11/30/2011	EP2389350A1 Methods for making valerenic acid derivatives and their use
11/30/2011	EP2389227A1 Methods for treating acute myocardial infarctions and associated disorders
11/30/2011	EP2389226A1 Bridged and fused heterocyclic antidiabetic compounds
11/30/2011	EP2389197A1 Combinations comprising methotrexate and dhodh inhibitors
11/30/2011	EP2389196A1 Phd2 inhibition for blood vessel normalization, and uses thereof
11/30/2011	EP2389187A1 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
11/30/2011	EP2389186A2 A phytochemical composition and a process thereof
11/30/2011	EP2389183A1 Phosphate management with small molecules
11/30/2011	EP2389182A1 Treatment of neurotrophic factor mediated disorders
11/30/2011	EP2389181A1 Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use
11/30/2011	EP2389180A1 Methods of treating muscular dystrophies
11/30/2011	EP2389179A1 Use of deferiprone for treatment and prevention of iron-related eye disorders
11/30/2011	EP2389178A2 Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
11/30/2011	EP2389177A1 A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
11/30/2011	EP2389176A1 Novel metabolic disease therapy
11/30/2011	EP2389175A1 Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
11/30/2011	EP2389174A2 Chronotherapeutic pharmaceutical composition
11/30/2011	EP2389173A1 New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
11/30/2011	EP2389172A1 Abuse resistant melt extruded formulation having reduced alcohol interaction
11/30/2011	EP2389171A2 Use of pterosin compounds for treating diabetes and obesity
11/30/2011	EP2389169A1 Controlled release formulations with continuous efficacy
11/30/2011	EP2389168A2 Pharmaceutical compositions comprising phosphate-binding polymer
11/30/2011	EP2389166A1 Pharmaceutical composition comprising aleglitazar
11/30/2011	EP2389165A2 Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
11/30/2011	EP2389164A2 Pharmaceutical compositions comprising a hcv polymerase inhibitor prodrug
11/30/2011	EP2389161A2 Controlled release systems from polymer blends
11/30/2011	EP2389160A1 Continuous double emulsion process for making microparticles
11/30/2011	EP2389159A1 Process for preparing particles of opioids and compositions produced thereby
11/30/2011	EP2389157A1 Drug delivery system for use in the treatment of vascular and vessel-related pathologies
11/30/2011	EP2389155A2 Orally disintegrating tablets for the treatment of pain
11/30/2011	EP2389078A1 Dual cation dual anion coordination complexes
11/30/2011	EP2389077A1 Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health
11/30/2011	EP2389071A1 Biofilm-removing antimicrobial compositions and uses thereof
11/30/2011	EP2389068A1 Hedgehog pathway inhibitors
11/30/2011	EP2389067A1 Antimicrobial molecules for treating multi-drug resistant and extensively drug resistant strains of mycobacterium
11/30/2011	EP2310383B1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
11/30/2011	EP2307420B1 Nalmefene di-ester prodrugs
11/30/2011	EP2303228B1 Fosphenytoin composition
11/30/2011	EP2276756B1 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
11/30/2011	EP2271617B1 Substituted 4-hydroxy-n- (4-hydroxyphenyl) indoles as estrogenic agents
11/30/2011	EP2231629B1 Modulators for amyloid beta
11/30/2011	EP2219477B1 Composition for regulating lipid metabolism
11/30/2011	EP2217583B1 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/30/2011	EP2217231B1 Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
11/30/2011	EP2156833B1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
11/30/2011	EP2089006B1 Medicament with controlled release containing galanthamine
11/30/2011	EP2062886B1 Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
11/30/2011	EP2041069B1 Benzyl amines, a process for their production and their use as anti-inflammatory agents
11/30/2011	EP2040707B1 Combination of atorvastatin with a phosphodiesterase 4 inhibitor for the treatment of inflammatory pulmonary diseases
11/30/2011	EP2010289B1 Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol
11/30/2011	EP1940251B1 Dietary supplement energy-providing to skeletal muscles and protecting the cardio vascular tract
11/30/2011	EP1938824B1 Medicine, food and drink or feed containing sphingomyelin
11/30/2011	EP1934234B1 Novel amine-borane compounds and uses thereof
11/30/2011	EP1904108B1 Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin
11/30/2011	EP1899324B1 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
11/30/2011	EP1888578B1 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo [4,5-c] quinolinyl)-phenyl]propionitrile as lipid kinase inhibitor
11/30/2011	EP1841433B1 Composition for treating central nervous system disorders

1 ... 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 ... 7860